This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US
by Zacks Equity Research
Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.
JNJNegative Net Change MRNANegative Net Change OCGNPositive Net Change BNTXNegative Net Change
biotechs
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
REGNNegative Net Change GSKNegative Net Change BIIBNegative Net Change VRTXNegative Net Change NVAXNegative Net Change
biotechs pharmaceuticals
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
BIIBNegative Net Change AMGNPositive Net Change GILDNegative Net Change MRNANegative Net Change IBBNegative Net Change INOPositive Net Change XBINegative Net Change CLOVPositive Net Change IBBQNegative Net Change
biotechs etfs
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.
REGNNegative Net Change GSKNegative Net Change RGENNegative Net Change VIRNegative Net Change
biotechs pharmaceuticals
RAPT Reports Positive Data From Atopic Dermatitis Study
by Zacks Equity Research
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
REGNNegative Net Change SNYNegative Net Change RGENNegative Net Change RAPTPositive Net Change
biotechs
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases
by Zacks Equity Research
CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.
VRTXNegative Net Change BAYRYNegative Net Change KMDANegative Net Change CRSPNegative Net Change
biotechs
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
BIIBNegative Net Change NERVPositive Net Change VTGNNegative Net Change
biotechs
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
RGENNegative Net Change ADPTPositive Net Change AXSMPositive Net Change BNTXNegative Net Change
biotechs
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
by Zacks Equity Research
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
REGNNegative Net Change LLYNegative Net Change GILDNegative Net Change COCPNegative Net Change
biotechs
Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.
JNJNegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
by Zacks Equity Research
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
BMYNegative Net Change EXELPositive Net Change NKTRNegative Net Change RGENNegative Net Change
biotechs medical
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.
BIIBNegative Net Change SGMOPositive Net Change DNLINegative Net Change
biotechs
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
BIIBNegative Net Change FBTNegative Net Change SBIONegative Net Change BTECPositive Net Change ARKGNegative Net Change GNOMNegative Net Change CLOVPositive Net Change
biotechs etfs
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
VRTXNegative Net Change EDITPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
by Zacks Equity Research
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
PFENegative Net Change NVONegative Net Change ASNDNegative Net Change
biotechs
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream
by Zacks Equity Research
Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.
REGNNegative Net Change SNYNegative Net Change NVSNegative Net Change INCYNegative Net Change
biotechs
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
GSKNegative Net Change NVONegative Net Change GILDNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.
BMYNegative Net Change MRKNegative Net Change RGENNegative Net Change
biotechs
Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks
by Zacks Equity Research
Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.
JNJNegative Net Change MRNANegative Net Change OCGNPositive Net Change BNTXNegative Net Change
biotechs
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients.
REGNNegative Net Change VRTXNegative Net Change RGENNegative Net Change BNTXNegative Net Change
biotechs
COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart
by Indrajit Bandyopadhyay
The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.
JNJNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals
ETFs to Win as Moderna Seeks COVID-19 Vaccine Nod for Teens
by Sweta Jaiswal, FRM
Moderna (MRNA) is once again in the spotlight with an impressive update relating to mRNA-1273.
MRNANegative Net Change IBBNegative Net Change BBHNegative Net Change IDNANegative Net Change
biotechs etfs
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
by Zacks Equity Research
Omeros (OMER) announces initial results from a phase I study of OMS906.
CPIXPositive Net Change RGENNegative Net Change OMERNegative Net Change XNCRNegative Net Change
biotechs medical pharmaceuticals
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children
by Zacks Equity Research
The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.
VRTXNegative Net Change RGENNegative Net Change TECHNegative Net Change KMDANegative Net Change
biotechs
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
ARNAPositive Net Change RGENNegative Net Change TECHNegative Net Change KMDANegative Net Change
biotechs